Antifibrotic drugs as therapeutic tools in resistant melanoma
Abstract Melanoma is the most aggressive form of skin cancer. Together with the recent advances in immunotherapy, targeted therapy with inhibitors of the Mitogen Activated Protein Kinase (MAPKi) pathway including BRAF and MEK inhibitors has greatly improved the clinical outcome of these patients. Un...
Saved in:
| Main Authors: | Berta Sanchez‐Laorden, M Angela Nieto |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-02-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202115449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems
by: Xiaoyong Hu, et al.
Published: (2025-06-01) -
Melanoma innervation, noradrenaline and cancer progression in zebrafish xenograft model
by: Francesca Lorenzini, et al.
Published: (2025-05-01) -
Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties
by: Michal Selc, et al.
Published: (2025-08-01) -
An Antimicrobial and Antifibrotic Coating for Implantable Biosensors
by: Sofia Wareham-Mathiassen, et al.
Published: (2025-03-01) -
Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic Implications
by: Bhuvanesh Sukhlal Kalal
Published: (2025-04-01)